The differences between the treatment and control groups were significant. Patients who received tocilizumab were hospitalized for a much shorter length of time, including time spent on a ventilator, than those who received the standard treatment. The time spent on ventilation was reduced by ten days, the time spent in intensive care by eight days, and the total hospital stay by ten days. The treatment was not associated with serious adverse events.
